Document:

Stereotaxis Advisory Board and Consulting Agreement

 Exhibit 10.2 
 Eric N. Prystowsky, MD 
 STEREOTAXIS ADVISORY BOARD AND CONSULTING
AGREEMENT 
 This Agreement is made by and between Stereotaxis, Inc., a Delaware corporation (hereinafter
“Company”), with offices located at 4320 Forest Park Avenue, Suite 100, St. Louis, Missouri 63108, USA, and Eric N. Prystowsky, MD (hereinafter “Consultant”), with offices located at 958 Laurelwood, Carmel, IN 46032. 

WHEREAS, Consultant is affiliated with St. Vincent’s Health System (hereinafter “Institution”) and is affiliated
with Ascension Health Ventures (hereinafter “Ascension”). Consultant has been involved in medical research in fields of particular interest to the Company and has achieved recognition as an international leader in the field of cardiac
electrophysiology. The Company wishes to retain Consultant in a consulting capacity and as a member of the Stereotaxis Advisory Board, and Consultant desires to perform such consulting services. 

WHEREAS, the Company has developed and acquired substantial information and expertise in the Field of Interest, with or without the use
of Company Technology, and will disclose to Consultant such information as Company deems appropriate about Company Technology to assist Consultant in developing ideas for the application of such Company Technology. 

In consideration of the foregoing, and for other good and valuable consideration, the adequacy and receipt of which are hereby
acknowledged, the parties agree as follows: 
 1. Definitions. 

1.1 Field of Interest means computer-controlled or assisted navigation and delivery systems for interventional disposable devices,
with or without the use of magnetic devices or systems, and related interventional workstations, devices, and integrated information networks, used in or with interventional medical procedures. 

1.2 Company Technology means all information, data, equipment, devices, inventions, discoveries, trade secrets, know-how,
software, hardware, and associated intellectual property rights in the Field of Interest that are owned, developed, or licensed by Stereotaxis. 

2. Services. 

2.1 Consultant shall advise the Company’s management, employees, and agents, at reasonable times, in matters related to
computer-controlled or assisted navigation systems, devices, and therapies (hereinafter “Field of Interest”), as requested by the Company. In response to a request by an officer or duly appointed representative of the Company, Consultant
shall provide consultation over the telephone, in person at Consultant’s office, or through written correspondence. Such consultation will include reviewing activities and developments in the Field of Interest and advising on new products and
applications for the Company Technology. In addition, Consultant shall, from time-to-time, make himself available in person at the Company’s offices or other locations as agreed upon. The consulting services required under this Section 2.1
are described in greater detail on Schedule 2.1, incorporated herein by reference. 

  
 Page 1 of 17

 2.2 Consultant shall participate as a member and Chairman of the Stereotaxis Advisory Board
(hereinafter, “Advisory Board”) and use his best efforts to attend Advisory Board meetings, anticipated to be at least one (1) time per year. 
 3. Consideration. 
 3.1 In consideration for the consulting,
advisory, development, and clinical research services provided by Consultant under Section 2 hereof, Consultant will be compensated as described below: 
 (a) The Company agrees to pay Consultant a cash stipend of US $28,800.00 per calendar quarter, in consideration of Consultant’s provision of all services described in Section 2 hereof at the
specific request of the Company, and shall be limited to such amount of time as the parties may agree in advance. Payment shall be made at the end of each calendar quarter for documented time spent during the three (3) months of that quarter.
For purposes of this Agreement, services provided shall consist of at least 36.0 hours per calendar quarter. The Company shall not reimburse for time and/or services otherwise billable to insurance carriers or other third parties. 

(i) In the event Consultant spends fewer than 36.0 hours per quarter, Consultant’s remuneration shall be adjusted pro rata based on
an hourly rate of US $800.00, and, upon payment for the applicable quarter, the Company shall inform Consultant, in writing (in accordance with Section 15), that the service requirements for the given period have not been met and pro rata
adjustments have been made. 
 (ii) Documented time spent (Section 3.1(b)) for services provided in excess of 36.0 hours in a
given calendar quarter may be carried forward toward remuneration in subsequent calendar quarters, as are appropriate. 
 (b)
Consultant agrees to maintain a record of his days spent and activities performed pursuant to time sheets in substantially the form attached as Exhibit A to this Agreement (or other form, electronic or otherwise, that may be approved by the
Company). Such time sheets shall be treated as invoices for payments due pursuant to this Section 3 and Company shall have no obligation to make payment unless and until Consultant shall have submitted his time sheet for the applicable calendar
quarter. The Company shall not reimburse for time and/or services otherwise billable to insurance carriers or other third parties. 
 (c) The Company agrees to reimburse Consultant for reasonable and documented travel and related expenses actually incurred by Consultant and pre-approved in writing by the Company, in accordance with
Stereotaxis standard expense reimbursement policies, as amended from time to time. Consultant shall also maintain records of his actual expenses incurred in connection with the performance of the services under the Agreement. 

(d) Within thirty (30) days following the end of each calendar quarter, Consultant shall submit to Company his timesheets and
expense reports, and the Company shall issue a check for the applicable amount within thirty (30) days following receipt of such reports or otherwise in accordance with the Company’s standard payment cycle. The Company shall not reimburse
for time and/or services otherwise billable to insurance carriers or other third parties. 

  
 Page 2 of 17

 3.2 Consultant acknowledges and agrees that the fees and expenses provided for above
represent Company’s full and complete obligation for any and all advisory and consulting services to be rendered, and expenses incurred, on behalf of the Company under this Agreement. 

3.3 In the event that Consultant is requested to serve as a principal investigator of one or more of the Company’s human clinical
trials, Consultant acknowledges that, to the extent required by Title 21 Code of Federal Regulations Part 54, the Company will disclose all financial compensation to Consultant from the Company under this Agreement on a written Form 3454, which will
be submitted by the Company to the Food and Drug Administration (FDA). Termination of this Agreement shall not modify the disclosure requirements specified in this section for relevant submissions to the FDA. Consultant’s services as a
principal investigator in any Company-sponsored clinical trials shall not be subject to this Agreement (other than this Section 3.3). 
 3.4 (a) The Company and Consultant acknowledge and agree that the consideration set forth in this Section 3 represents the fair market value for the services to be rendered under this Agreement, and
no amount payable hereunder is intended to constitute a payment for the inducement of patient referrals, the purchase, lease, or order of any item or service, or the recommending or arranging for the purchase, lease, or order of any item or service.

 (b) This Agreement shall be construed to the fullest extent possible to be in compliance with and
permitted by all U.S., non-U.S., state, or other local laws, statutes, rules, and regulations. If a Triggering Event (as defined below) occurs after the date hereof, the parties agree that they shall amend this Agreement solely to the extent
necessary to comply with the item giving rise to the Triggering Event, and in a manner that shall preserve the underlying economic and financial arrangements between the parties with the least changes to the parties’ expectations hereunder. For
purposes of this Section 3.4, a “Triggering Event” shall mean any U.S., state, or local governmental agency, or any other non-U.S. local governmental agency, or any court or administrative tribunal, passing, issuing, or promulgating
any law, final rule, final regulation, or rendering from an evidentiary proceeding any order, decision, or judgment (including but not limited to those relating to any final regulations or administrative interpretations promulgated under applicable
anti-kickback or self-referral statutes) which in the good faith and reasonable judgment of a party hereto materially and adversely affects such party’s licensure or certification, ability to obtain any material benefit hereunder or under any
payment program to which it is a party or ability to perform a material obligation hereunder, or renders this agreement unlawful. If the parties in good faith cannot agree on a necessary amendment under this Section 3.4 within thirty
(30) days of notification of the Triggering Event, then this Agreement shall terminate without further action on the
30th day. 

4. Term. 
 4.1
This Agreement shall have an initial term of one (1) year from the Effective Date (the “Term”). This Agreement may be renewable for periods (the “Renewal Term”) up to a cumulative term of two (2) years from the
Effective Date (collectively, the “Term”). All such 

  
 Page 3 of 17

 
Renewal Terms shall be valid only upon the execution of a written agreement by Consultant and the Company, approved by a Company Compliance Officer pursuant to Section 21 of the Agreement,
and executed prior to the end of the then current Initial or Renewal Term. 
 4.2. Termination. 

(a) In the event that either Party hereto shall commit a material breach with respect to the performance of any of its obligations
hereunder and if such breach shall not be remedied within thirty (30) days after written notice of such breach by the nonbreaching Party to the breaching Party, then the nonbreaching Party may, but shall not be obligated to, terminate this
Agreement immediately upon further notice. Any termination hereof shall not waive any legal or equitable remedy available to the nonbreaching Party against the breaching Party by reason of such breach. Either Party hereto shall be deemed to be in
breach hereunder if at any time it shall be adjudicated bankrupt or insolvent, or an order shall be entered, remaining unstayed by appeal or otherwise for sixty (60) days, appointing a receiver or trustee for such Party or any of its
properties, or approving a petition seeking reorganization or other relief under the bankruptcy or similar laws of the United States, any U.S. state or applicable foreign law, or such Party shall file a petition to take advantage of any statutes for
the protection of debtors, or make a general assignment for the benefit of creditors. Upon the occurrence of any such breach under the provisions of the preceding sentence, the nonbreaching Party shall be entitled to terminate this Agreement
immediately upon written notice given to the breaching Party. 
 (b) In addition, either party may terminate this Agreement upon
thirty (30) days’ written notice to the other party. 
 (c) In the event of a termination of this Agreement pursuant
to this section, the parties shall not enter into any new agreements or financial arrangements with respect to the subject matter hereof from the date of termination until the next anniversary date of the Effective Date. 

(d) Upon termination all accrued payments as of the date of the notice of termination will be paid by the Company. 

(e) This Agreement shall continue in full force and effect following any Change of Control of the Company (as hereinafter defined)
through the end of the term, provided that the termination rights of the parties in the event of breach, set forth in Section 4.2(a), shall not be affected by such Change of Control. “Change of Control” shall mean 

(A) any merger or other business combination involving the Company after which the former stockholders of the Company own less than
fifty percent (50%) of the outstanding stock for the surviving company, 
 (B) any sale of all or substantially all of the
assets of the Company, or any similar transaction, 
 (C) any transaction or series of related transactions by the Company in
which in excess of fifty percent (50%) of the voting securities of the Company are transferred to any third party (whether a single person or a group of persons as defined in the US securities laws, or

  
 Page 4 of 17

 (D) any similar transactions or series of transaction (as reasonably determined by the
Company). 
 4.3 Modifications 
 The material terms of this agreement, including the services performed and the compensation to be paid, may not be modified within one (1) year following the Effective Date of this Agreement, nor any
more frequently than annually thereafter. 
 5. Certain Other Contracts. 

5.1 Consultant will not disclose to the Company any information that Consultant is obligated to keep secret pursuant to an agreement
with, or other duty of confidentiality to, a third party, and nothing in this Agreement shall be deemed to impose any obligation on Consultant to the contrary. In the event that either party has a contractual or ethical obligation to disclose the
existence of this Agreement to a third party the other party hereby consents to such disclosure, provided that the disclosing party notifies the other party of such disclosure. 

5.2 Consultant shall not perform consulting work hereunder during the time that is required to be devoted to the Institution or to any
other third party. Consultant shall not use the time, funding, resources, or facilities of the Institution, or any other third party to perform consulting work hereunder, and Consultant shall not perform the consulting work hereunder in any manner
that would give the Institution or any third party any claim of benefit to, or rights (including intellectual property rights) in the product of such work. 
 5.3 Consultant has disclosed on the attached Schedule 5.3 all present (and during the term of this Agreement Consultant shall promptly disclose to the Chief Executive Officer of the Company
any subsequent) actual or potential conflicts between this Agreement and any other agreements under which Consultant owes any duties or obligations, including any agreements or understandings that Consultant has with any person or firm relating to
the Field of Interest. 
 6. Exclusive Services During The Term. Consultant agrees that during the Term of this Agreement and for
a period ending one (1) year after the expiration or earlier termination of this Agreement pursuant to Section 4 or otherwise, he will not directly or indirectly either 

(a) provide any consulting, advisory, development, and clinical research or other services to any other business or commercial entity
which competes with the Company in the Field of Interest or 
 (b) participate in the formation of any business or commercial
entity which competes with the Company in the Field of Interest. 
 7. Disclosure of Discoveries to the Company. Subject to
Consultant’s confidentiality obligations to third parties, during the term of this Agreement, Consultant will use his best efforts to disclose to the Chief Executive Officer of the Company, on a confidential basis, technology and product
opportunities which come to the attention of Consultant in the Field of Interest, and any idea, concept, invention, improvement, discovery, process, formula, technique, or method, or other intellectual property relating to, or useful in, the Field
of Interest, whether or not patentable or copyrightable (hereinafter “Discoveries”). 

  
 Page 5 of 17

 8. Consultant Discoveries. Consultant will promptly and fully disclose to the Chief Executive
Officer of the Company (or his designee) any Discoveries conceived, developed, or first reduced to practice by Consultant or by the Institution or anyone working on their respective behalves, either alone or jointly with others, while performing
services pursuant to this Agreement (the “Consultant Discoveries”). Consultant agrees to, and hereby does, assign to the Company all of his right, title, and interest in and to any such Consultant Discoveries. Consultant agrees to take
such actions and execute such documents as reasonably required by Company to secure and enforce Company’s rights in Consultant Discoveries, including the documents required for Company to apply for, obtain, and enforce patents or copyrights in
any and all countries on such Consultant Discoveries. Consultant hereby irrevocably designates the Secretary of the Company as his agent and attorney-in-fact to execute and file any such document and to do all lawful acts necessary to apply for and
obtain patents and copyrights, and to enforce the Company’s rights under this paragraph. This Section 8 will survive the termination of this Agreement with respect to Consultant Discoveries. Without limiting the foregoing, but subject to
Consultant’s rights in Section 10 hereof, the Company shall have the exclusive right to use and exploit economically, to divulge, to publish, to record, to translate, to distribute, and to modify all the papers, publications, and any other
document or information relating to Company Technology or otherwise within the Field of Interest. The documents, papers, and other information (including such Consultant Discoveries) shall not be transferred, communicated to third parties, divulged,
or published for any reason without the Company’s prior written consent. 
 9. Health Information  

9.1 The Parties recognize a common goal of securing the integrity of all individually identifiable health information and according that
information the highest possible degree of confidentiality and protection from disclosure. 
 (a) All individually identifiable
health information (including information relating to patients and/or study subjects whose identities may be ascertained by the exercise of reasonable effort through investigation or through use of other public or private databases) shall be treated
as confidential by the Parties in accordance with applicable federal, state, and local laws, rules, and regulations governing the confidentiality and privacy of individually identifiable health information, including, but without limitation, to the
extent that each party is subject to it, the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and any regulations and official guidance promulgated thereunder; and the Parties agree to take such additional steps as may
be required to ensure that the Parties are and remain in compliance with HIPAA regulations and official guidance. 
 (b) The
Company, even if not a covered entity under HIPAA, recognizes that the Company has the responsibility to protect all individually identifiable health information consistent with the protections afforded to that information as Confidential
Information set forth above; and only to use and disclose such information as necessary to discuss and analyze the results of a clinical case, to ensure research integrity, to communicate with the Food and Drug Administration [FDA] and other
regulatory authorities, and otherwise as required by law or as permitted by authorizations or consents signed by affected patients, or waiver of authorization 

  
 Page 6 of 17

 
granted by an Institutional Review Board [IRB] overseeing clinical protocols or that IRB’s affiliated Privacy Board (the “Permitted Activities”); and to restrict the use and
disclosure of any individually identifiable health information gained through the Permitted Activities to its workforce, contractors, subcontractors, study collaborators, and agents (collectively “Recipients of Patient Information”) who
must have access to that information in order directly to support or facilitate the Permitted Activities; and to notify all Recipients of Patient Information of the requirements regarding protecting, using, and disclosing such information in the
fulfillment of their assigned duties. 
 9.2 Based on the Institution’s internal operating procedures and/or regulations,
Consultant assumes all responsibility to determine if any IRB clearance or informed patient consent is required regarding any clinical case information provided by Consultant to the Company. The Company assumes no responsibility for lack of IRB
approvals or consent of patients in the event that the Consultant fails to follow regulations pertaining to informed consent and IRB approvals. Upon request, Consultant shall provide the Company with written verification of IRB and/or patient
consent approvals or waiver. 
 10. Confidentiality. 
 10.1 Consultant acknowledges that, during the course of performing services pursuant to this Agreement, the Company will be disclosing information to Consultant, including information about Company
Technology, and that Consultant will be developing information related to the business of the Company, including but not limited to Discoveries, Consultant Discoveries, projects, products, prospective suppliers, prospective customers, personnel,
business plans, and finances, as well as, other commercially valuable information (hereinafter “Company Information”). Consultant acknowledges that the Company’s business is extremely competitive, dependent in part upon the
maintenance of secrecy, and that any improper disclosure of the Company Information would result in serious and irreparable harm to the Company. 
 10.2 Consultant agrees that Consultant shall only use the Company Information in connection with providing consulting services to Company hereunder, and that Consultant shall not use Company Information
in any way that is detrimental to the Company. 
 10.3 Consultant shall not disclose, directly or indirectly, the Company
Information to any third person or entity, other than to officers or duly appointed representatives or agents of the Company. Consultant will treat the Company Information as confidential and the proprietary property of the Company. 

10.4 Nothing in this Agreement shall prevent Consultant from disclosing or using information that 

(a) Consultant can prove by documentary evidence was already in his possession and at his free disposal before the disclosure to him
hereunder; or 
 (b) is subsequently disclosed to Consultant by a third party not under any obligations of confidentiality to
the Company; or 

  
 Page 7 of 17

 (c) is or becomes generally available to the public through no fault of Consultant; or

 (d) is independently developed by Consultant without the use of any other Confidential Information of the Company; or

 (e) is required by law to be disclosed by Consultant, subject to Section 10.5 below. 

10.5 Consultant may disclose Confidential Information hereunder solely to the extent such disclosure is reasonably necessary in
connection with submissions to any governmental authority in connection with this Agreement or in filing or prosecuting patent applications contemplated under this Agreement, prosecuting or defending litigation, complying with applicable laws or for
the purposes expressly permitted by this Agreement; provided that in the event of any such disclosure of the Company’s Confidential Information by Consultant, Consultant will, except where impracticable, give reasonable advance notice to
the Company of such disclosure requirement so that the Company may seek a protective order and or other appropriate remedy or waive compliance with the confidentiality provisions of this Section 10, and will reasonably cooperate with the
Company in any efforts to secure confidential treatment of such Confidential Information required to be disclosed. 
 10.6
Whenever requested by Company, Consultant will promptly return to the Company all materials containing or reflecting Company Information as well as data, records, reports, and other property, furnished by the Company to Consultant or produced by
Consultant in connection with services rendered hereunder, together with all copies of any of the foregoing. Notwithstanding such return, Consultant shall continue to be bound by the terms of the confidentiality provisions contained in this
Section 10 for a period of four (4) years after the expiration or termination of this Agreement. 
 11. Publication.
Consultant may publish or orally disclose results of Consultant’s work performed pursuant to the Agreement only with the prior written consent of Company (such consent not to be unreasonably withheld) provided that Consultant may make all
requisite disclosures to regulatory authorities. 
 12. Use of Name. 

12.1 Neither party shall use the name of the other for any commercial purpose without the prior written consent of the named party for
the specific use. 
 12.2 Notwithstanding the foregoing, Consultant understands that his name and his affiliation with the
Institution may appear in disclosure documents required by securities laws, and in other U.S. or other applicable non-U.S. regulatory and administrative filings in the ordinary course of the Company’s business. It is also understood that the
name of Consultant and Consultant’s affiliation with the Institution may appear in such filings and disclosure documents in connection with the Company’s Scientific Advisory Board. The foregoing uses in this Section 12.2 will be
deemed to be non-commercial uses. 

  
 Page 8 of 17

 13. Consultant Representations, Warranties and Covenants. 

13.1 Representations and Warranties. Consultant represents and warrants to the Company that: 

(a) he is free to enter into this Agreement and that neither this Agreement nor the performance Consultant’s obligations hereunder
present actual or potential conflicts with any other agreements, understandings, policies, or other arrangements (including, without limitation, of the Institution) under which Consultant owes any duties or obligations, including any agreements,
understandings, policies or other arrangements that Consultant has with any person or firm relating to the Field of Interest; and 
 (b) neither the execution of this Agreement nor the performance of Consultant’s obligations under this Agreement will result in a violation or breach of any other obligation of confidentiality or any
employment, consulting, advisory, development, or other agreement by which Consultant is bound (including with respect to the Institution) or, to Consultant’s knowledge, of any U.S. or applicable non-U.S. law or regulation. 

13.2 Covenants. During the term of this Agreement, Consultant will not enter into any arrangement or agreement in conflict with
this Agreement and agrees to promptly disclose to the Company any subsequent actual or potential conflicts with any agreements, understandings, policies, or other arrangements with any third party. Consultant shall indemnify, defend, and hold the
Company harmless against any and all liability and expense which the Company might incur as a result of any breach of the representations, warranties, and covenants under this Agreement. 
 14. Disclosures. 
 14.1 Disclosure of Agreement. Consultant
represents and warrants that he has no contractual or other obligation to disclose the existence of this Agreement to St. Vincent’s Health System, Ascension Health Ventures, or any other institution or organization with which Consultant is
affiliated. In the event that either party has a contractual, legal, or ethical obligation to disclose the existence of this Agreement to a third party, the other party hereby consents to such disclosure, provided that the disclosing party notifies
the other party of such disclosure. The Company may disclose the existence of, and some or all of the terms of, this Agreement to St. Vincent’s Health System, Ascension Health Ventures, or any other institution with which Consultant is
affiliated for the purpose of obtaining such institution’s acknowledgement and agreement relating to the Company’s ownership of any Consultant Discoveries as set forth herein. 

14.2 Disclosure of Fees and Services. Consultant acknowledges and agrees that all consulting arrangements and the Company’s
relationship with Consultant and/or Institution are subject to public disclosure in Company communications, including on the Company’s website. Such disclosure may include, but is not limited to, compensation paid to Consultant or Institution
for services, payments for travel expenses (lodging, transportation, and meals), consulting fees, royalties, equity, discounts, rebates, and/or intellectual property terms. Disclosures may be made for the year-to-date and the prior calendar year.
Disclosures may include any stock and/or stock options provided to the consultant and/or service provider from year 2005 forward. 

  
 Page 9 of 17

 15. Notices. All notices, requests, or other communications to a party will be sufficient if
contained in a written instrument, addressed to such party at the address set forth below or such other address as may be designated in writing by the addressee to the addresser, if: delivered in person, or sent by overnight courier with record of
receipt, or sent by fax or email with confirming copy sent by mail with receipt acknowledged by the below-named addressee or its authorized designee: 
 In the case of the Company: 
 Stereotaxis, Inc. 

4320 Forest Park Avenue, Suite 100 
 St. Louis, Missouri 63108 
 Attention: Clinical Compliance 

Email: peter.takes@stereotaxis.com 
 Fax: 1-314-667-3880 
 In the case of Consultant: 

Eric N. Prystowsky, MD 
 958 Laurelwood 
 Carmel, IN 46032 

Email: Eprystow@thecaregroup.com 
 Fax: 
 or to such other address as may have been designated by the Company or Consultant by notice
to the other given as provided herein. 
 16. Independent Contractor: Withholding. Consultant will at all time be an independent
contractor, and as such will not have authority to bind the Company. Consultant will not act as an agent nor shall he be deemed to be an employee of the Company for the purposes of any employee benefit program, unemployment benefits, or otherwise.
Consultant recognizes that no amount will be withheld from his compensation for payment of any federal, state, or local taxes and that Consultant has sole responsibility to pay such taxes, if any, and file such returns as shall be required by
applicable laws and regulations. Consultant shall not enter into any agreements or incur any obligations on behalf of the Company. 
 17.
Assignment. Due to the personal nature of the services to be rendered by Consultant, Consultant may not assign this Agreement. The Company may assign all rights and liabilities under this Agreement (as a group with other similar
agreements with members of the Scientific Advisory Board) to a subsidiary or an affiliate or to a successor to all or a substantial part of its business and assets without the consent of Consultant. Subject to the foregoing, this Agreement will
inure to the benefit of and be binding upon each of the heirs, assigns, and successors of the respective parties. 
 18.
Severability. If any provision of this Agreement shall be declared invalid, illegal, or unenforceable, such provision shall be severed and the remaining provisions shall continue in full force and effect. 

  
 Page 10 of 17

 19. Remedies. Consultant acknowledges that the Company would have no adequate remedy at law
to enforce Sections 6, 8, and 10 hereof. In the event of a violation by Consultant of such Sections, the Company shall have the right to obtain injunctive or other similar relief, as well as any other relevant damages, without the requirements of
posting bond or other similar measures. 
 20. Arbitration. Any and all claims or disputes between the Company and Consultant
arising out of or relating to the Agreement, other than for injunctive relief, shall be decided by arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association currently in effect at that time, which shall
be the parties’ sole remedy at law or in equity. Notice of a demand for arbitration shall be filed in writing with the other party to this Agreement and with the American Arbitration Association and shall be made within a reasonable time after
the dispute arises. Any award rendered by the arbitrator or arbitrators shall be final and judgment may be entered thereupon in accordance with applicable law in any court having jurisdiction thereof. 

20.1 In the event of any dispute, disagreement, arbitration, or litigation as between the parties to the Agreement, then in such event to
the extent the prevailing party has incurred costs and expenses to retain the services of an attorney to enforce or defend the Agreement or any of the terms or portion thereof, the non-prevailing party shall pay all such reasonable costs thereby
expended including, but not limited to, attorney’s fees, court costs, costs of arbitration, and costs of litigation in the event injunctive relief is requested. 
 20.2 Upon written notice received, either party hereto shall have a reasonable period of time (but in no event to exceed thirty (30) days) within which to cure any default or failure to perform;
provided, however, that no irreparable harm shall have occurred as a result of such default or failure to perform. 
 21. Governing
Law. This agreement shall be interpreted, and the rights of the parties determined in accordance with the substantive laws of the State of Missouri, USA, without regard to conflicts of laws principles. This Agreement sets forth the entire
understanding of the parties with respect to the subject matter herein, supersedes all prior agreements between the parties, and may only be amended in writing, specifically referencing this agreement and signed by both Company and Consultant. No
amendments shall be valid without endorsement by a Company Compliance Officer. 
 This agreement contains binding
arbitration provisions that may be enforced by the parties. 
 [Signature page follows] 

  
 Page 11 of 17

 IN WITNESS WHEREOF, this Agreement may be executed in counterparts, each of which shall
constitute an original and all of which together shall constitute one instrument, effective as of the later of February 25, 2011, or the last date on which this Agreement is signed by the parties (the “Effective Date”). 

 

									
	STEREOTAXIS, INC.	 	 	 	 	 	 
					
	BY:	 	         /s/ Melissa Walker
	 		 	Compliance:	 	         /s/ Peter A. Takes

	Name: Melissa Walker	 		 	Name: Peter A. Takes, Ph.D., RAC
	Title: Sr. Vice President, Regulatory, Quality and Compliance	 		 	Title: Sr. Director, Clinical & Healthcare Compliance and Clinical Compliance Officer
					
	DATED:	 	         2/25/2011
	 		 	DATED:	 	         2/25/2011

				
		 		 		 	This agreement is not valid without endorsement by a Stereotaxis Compliance Officer.
				
	Consultant:	 		 		 	
					
	SIGNED:	 	     /s/ Eric N. Prystowsky
	 		 		 	
				
	Printed Name: Eric N. Prystowsky, MD	 		 		 	
					
	DATED:	 	     2/19/2011
	 		 		 	

  
 Page 12 of 17

 SCHEDULE 2.1 TO THE 

CONSULTING AGREEMENT 
 The
project consists of the development and commercialization of devices and the Company’s NavigantTM User Interface, to advance the Company’s computerized magnetic interventional system. The focus will be on the advancement of
applications in electrophysiology [EP]. 
 A. Consultant shall assist the project by offering professional knowledge, by reviewing new designs
and by participating in phantom, animal, and clinical studies of the Company. More specifically, Consultant shall play a leading role as the Chairman of the Scientific Advisory Board [SAB] in EP, to progress the development of this therapy into a
practical clinical solution, and shall assist the Company in developing devices related thereto. 
 B. Throughout this arrangement, the Company
will be responsible for implementing the designs and for coordinating all aspects of the project. Funding of research projects and clinical trials proposed by Consultant will be reviewed and negotiated on an individual basis. 

C. Services include, but are not limited to: 

(1) Providing business, clinical, and scientific input on the project, 
 (2) At the Company’s request and in the Company’s behalf, presenting at various conferences and seminars data and information on topics related to the use of the Company Technology, 

(3) Writing reports, 
 (4) Meetings with
Stereotaxis personnel, 
 (5) Evaluating product and providing feedback to the Company, 

(6) Writing professional/scientific publications, and 
 (7) Direct participation in phantom, animal, and clinical studies. 
 D. Specific deliverables and
duties shall include, but are not limited to: 
 (1) Providing ideas, know-how, and advice on the design of the Company’s software and
devices through discussions and meetings with design and engineering personnel at the Company’s facilities and elsewhere. 
 (2) Developing
protocols and helping to implement product trials in the US for electrophysiology indications. 
 (3) Assisting in marketing and educational
planning as requested by the Company, including without limitation the following: 
 (a) Preparing educational materials related
to Company Technology. 

  
 Page 13 of 17

 (b) Providing medical review of training, educational, marketing, and sales literature
developed by the Company. 
 (c) Responding to written and telephone inquiries from other physicians who are using Company
technology that have been referred to Consultant by the Company, provided the Company may request a copy of any written responses or a description of any oral disclosures made to such other physicians by Consultant. 

(4) Presenting at various conferences and seminars on the Company’s behalf on topics related to the use of the Company Technology. Additionally,
providing education and training to other physicians with respect to the Field of Interest and the Company Technology. Such education shall occur in formal training sessions consisting of five (5) to eight (8) physicians in each session.
No other faculty is expected to participate in such sessions. 
 E. During all presentations on behalf of the Company, including, but not
limited to, clinical/scientific presentations at professional conferences and seminars, Consultant shall not discuss or present data, information, commentary, and/or opinion on the off-label use of Company products in accordance with the intended
use approved or cleared by the US Food and Drug Administration and included in the product labeling and/or instructions for use. 
 F.
Consultant shall make an effort to provide to the Company for review, at least one (1) week prior to any scheduled event, a copy of all presentations to be made on behalf of the Company in accordance with this Agreement. The Company reserves
the exclusive right to modify, add, or delete content, and/or delete confidential and proprietary information. The consultant reserves the right to decline to present requested information he does not deem appropriate for the audience. 

G. The Company reserves the right, at its sole discretion, to maintain a copy of, as well as continued use of, all presentations made on behalf the
Company in accordance with this Agreement. 

  
 Page 14 of 17

 SCHEDULE 5.3 TO THE 

CONSULTING AGREEMENT 
 Any
actual or potential conflicts between this Agreement and any other agreements under which Consultant owes any duties or obligations, including any agreements or understandings that Consultant has with any person or firm relating to the Field of
Interest: 
 [LIST ALL CONFLICTING AGREEMENTS. IF NONE, INDICATE “NONE”.] 

  
 Page 15 of 17

 EXHIBIT A 

Form Time Record 
 NAME:
                                         
                                       
(Consultant’s Name) 
 MONTH:
                                        ,
20     
 [Attach additional sheets if necessary] 

 

					
	 Narrative Description of Consulting Duties

(provide reasonably detailed description of consulting activities)
	  	 Date/Time*

(Indicate actual working hours)
 *e.g., June 15, 2010 — 2:00 p.m.

to 4:15 p.m.
	  	 Total # hours

			
	 1.
	  		  	
			
	 2.
	  		  	
			
	 3.
	  		  	
			
	 4.
	  		  	
			
	 5.
	  		  	
			
	 6.
	  		  	
			
	 7.
	  		  	
			
	 8.
	  		  	
			
	 9. TOTAL
	  		  	

  

									
		 	Send to:
	 The above information is verified and accurately reflects services
 performed in accordance with the stipulations and conditions of
 my current consulting agreement
with Stereotaxis, Inc.
  
	 		 	 Stereotaxis, Inc.
 4320 Forest
Park Avenue, Ste. 100
 St. Louis, MO 63108
 ATTN: Kori Kach

	 Consultant
	 	  
	 		 	Ph 314-678-6168
		 		 		 	 Fax 314-678-6300

									
	 Date
	 	  
	 		 	

  
 Page 16 of 17

 

 

  

  
 Page 17 of 17First Amendment to Third Amended and Restated Credit Agreement

 Exhibit 10.1 
 FIRST AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT 
 THIS FIRST
AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) effective as of January 28, 2011, by and among BLOUNT, INC., a Delaware corporation (“Blount, Inc.”), OMARK PROPERTIES, INC., an
Oregon corporation (“Omark”), WINDSOR FORESTRY TOOLS LLC, a Tennessee limited liability company (“Windsor”) (Omark, Windsor and Blount, Inc. are sometimes collectively referred to herein as
“Borrowers” and individually as “Borrower”); the other Credit Parties signatory hereto; GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation (in its individual capacity, “GE Capital”), in
its capacity as Agent for the Lenders (as defined below) (“Agent”); and the other Lenders party hereto. 
 W
I T N E S S E T H: 
 WHEREAS, Borrowers, the other Credit Parties signatory thereto, the lenders party thereto from time to
time (the “Lenders”) and Agent are parties to that certain Third Amended and Restated Credit Agreement, dated as of August 9, 2010 (as further amended, restated, supplemented or otherwise modified from time to time, the
“Credit Agreement”); and 
 WHEREAS, Borrowers and the other Credit Parties have requested that Lenders amend
certain terms under the Credit Agreement; and 
 WHEREAS, Borrowers and Lenders have agreed to the requested amendments on the
terms and subject to the conditions set forth herein; 
 NOW THEREFORE, in consideration of the foregoing premises and other
good and valuable consideration paid by each party to the other, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree that all capitalized terms not otherwise defined herein (including the recitals and preamble
hereof) shall have the respective meanings ascribed to such terms in the Credit Agreement, after giving effect to this Amendment, and further agree as follows: 
  

	 	1.	Amendments to the Credit Agreement. 

 (a) Section 1.5 of the Credit Agreement is hereby amended by deleting subsection (c) thereof in its entirety and inserting the following in lieu thereof: 

“(c) If any payment on any Loan or any Commitment becomes due and payable on a day other than a Business Day, the due date for such
payment shall be extended to the next succeeding Business Day (except as set forth in the definition of LIBOR Period) without any increase in such payment as a result of additional interest or fees; provided, however, that such interest and fees
shall continue accruing as a result of such extension of time.” 
 (b) Section 1.9 of the Credit Agreement is hereby
amended by deleting the reference to “first Business Day” in the first sentence of subsection (b) thereof and replacing such reference with “first day”. 

 (c) Section 5 of the Credit Agreement is hereby amended by adding the following
Section 5.15 immediately following Section 5.14: 
 “5.15 Stock of Foreign Subsidiaries. In connection
with, and after giving effect to, the Foreign Subsidiary Reorganization, Borrowers shall cause (a) the Stock of BIH CV to be directly owned by one or more Credit Parties, (b) the Stock of the Foreign Stock Holding Company to be directly
owned by BIH CV and (c) except as set forth on Disclosure Schedule (5.15) and except as the result of any sale, transfer, conveyance, assignment or other disposition of the Stock of any Foreign Operating Subsidiary (other than to
any other Foreign Operating Subsidiary) occurring after the effectiveness of the Foreign Subsidiary Reorganization, or the acquisition of any Foreign Operating Subsidiary by a Credit Party, in each case that would otherwise be permitted hereunder,
the Stock of each Foreign Operating Subsidiary to be directly owned by the Foreign Stock Holding Company. For the avoidance of doubt, except as otherwise set forth on Disclosure Schedule (5.15), the Stock of each Foreign Operating Subsidiary
shall be directly owned by a Credit Party or the Foreign Stock Holding Company.” 
 (d) Section 6.1(a) of the Credit
Agreement is hereby amended and modified by deleting such section in its entirety and inserting the following in lieu thereof: 
 “(a) form any Subsidiary after the Closing Date; provided, however, that Credit Parties and their Subsidiaries may form new Subsidiaries after the Closing Date so long as (i) no
Default or Event of Default has occurred and is continuing, (ii) each Foreign Subsidiary so formed (other than (A) the Foreign Stock Holding Company and (B) any directly owned “shell” Subsidiary of the Foreign Stock Holding
Company that is formed solely for the purpose of consummating an acquisition by the Foreign Stock Holding Company that is permitted by Section 6.1(b)) is at least 80% owned by a Credit Party, (iii) each United States domestic Subsidiary so
formed is wholly owned by a Credit Party and (iv) contemporaneously with the formation of any such new Subsidiary, Credit Parties and each new Subsidiary, as applicable, comply with the provisions of Section 5.13; or”

 (e) Section 6.1(b) of the Credit Agreement is hereby amended and modified by deleting such section in its entirety and
inserting the following in lieu thereof: 
 “(b) merge with, consolidate with, amalgamate with, acquire all
or substantially all of the assets or Stock of, or otherwise combine with or acquire, any Person, except that (i) any Credit Party (other than Holdings) may merge into a Borrower and any Credit Party that is not a Borrower or Holdings may merge
into another Credit Party that is not a Borrower or Holdings, provided that Borrower Representative shall be the survivor of any such merger to which it is a party and, in the event of a merger between a Credit Party that is not a Borrower
and a Borrower, such Borrower shall be the survivor of any such merger, (ii) any Foreign Operating Subsidiary may merge into another Foreign Operating Subsidiary; provided, however, that Borrower Representative shall provide Agent
with 30 days prior written notice of such merger under this clause (ii), and (iii) the Foreign Subsidiary Reorganization shall not be prohibited by this Section 6.1(b). Notwithstanding the foregoing, any Credit Party, the Foreign
Stock Holding Company or any direct Subsidiary of the Foreign Stock Holding Company or a Credit Party (other than BIH CV) (so long as, in addition to the other requirements set forth below in this Section 6.1(b), with respect to any
acquisition by (A) Holdings, contemporaneously therewith, all assets so acquired are transferred to one or more other Credit Parties, and (B) a Foreign Subsidiary, such acquisition is in the form of an asset acquisition consummated by a
direct Subsidiary of the Foreign Stock Holding Company or a Credit Party (other than BIH CV) or the Subsidiary so acquired is held directly by the Foreign Stock Holding Company, in each case, immediately after giving effect to such acquisition and
the transactions consummated contemporaneously therewith (including the merger of the Person to be so acquired with a directly owned “shell” Subsidiary of the Foreign Stock Holding Company)) may acquire all or substantially all of the
assets or Stock of any Person (the “Target”) (in each case, a “Permitted Acquisition”) subject to the satisfaction of each of the following conditions (provided, that condition (vi) may be waived by Agent):

 (i) Agent shall receive at least ten (10) Business Days’ prior written notice of such proposed
Permitted Acquisition, which notice shall include a reasonably detailed description of such proposed Permitted Acquisition; 

  
 2 

 (ii) such Permitted Acquisition by a Credit Party or a Foreign Subsidiary
shall comprise a business, or those assets of a business, of a type reasonably related to the type engaged in by Borrowers as of the Closing Date, and which business would not subject Agent or any Lender to regulatory or third party approvals in
connection with the exercise of its rights and remedies under this Agreement or any other Loan Documents other than approvals applicable to the exercise of such rights and remedies with respect to Borrowers prior to such Permitted Acquisition;

 (iii) such Permitted Acquisition shall be consensual and shall have been approved by the Target’s board
of directors; 
 (iv) no additional Indebtedness, Guaranteed Indebtedness, contingent obligations or other
liabilities shall be incurred, assumed or otherwise reflected on a consolidated balance sheet of Credit Parties and Target after giving effect to such Permitted Acquisition, except, without duplication, (A) Loans made hereunder,
(B) ordinary course trade payables, accrued expenses and unsecured or secured Indebtedness of the Target to the extent no Default or Event of Default has occurred and is continuing or would result after giving effect to such Permitted
Acquisition and (C) Indebtedness permitted under Section 6.3(a)(iii), Section 6.3(a)(xi), Section 6.3(a)(xii) and Section 6.3(a)(xiii); 

  
 3 

 (v) the sum of all amounts payable in connection with all Permitted
Acquisitions (including all transaction costs and all Indebtedness, liabilities and contingent obligations incurred or assumed in connection therewith or otherwise reflected in a consolidated balance sheet of Borrowers and Target) shall not exceed
$125,000,000 per acquisition and $300,000,000 in the aggregate during the term of this Agreement, of which $150,000,000 (plus up to $50,000,000 which is funded directly by one or more Foreign Subsidiaries from cash on hand at such Foreign
Subsidiary) may be used for acquisitions that involve assets located in a jurisdiction outside of the United States, plus the amount of Stock issued by Holdings to any seller in connection with, and as the purchase price or portion of the purchase
price for, any Permitted Acquisition; 
 (vi) the Target shall not have negative earnings before income, taxes,
interest, depreciation and amortization (with such adjustments thereto as may be consented to by Agent, such consent not to be unreasonably withheld) for the trailing twelve-month period preceding the date of the Permitted Acquisition, as determined
based upon the Target’s financial statements for its most recently completed four fiscal quarter period for which financial statements are available; 
 (vii) the business and assets acquired in such Permitted Acquisition shall be free and clear of all Liens (other than Permitted Encumbrances); 

(viii) to the extent the assets being acquired in connection with any Permitted Acquisition are acquired by a Credit
Party, at or prior to the closing of such Permitted Acquisition, Agent will be granted a first priority perfected Lien (subject to Permitted Encumbrances) in all assets acquired pursuant thereto, and Credit Parties shall have executed such documents
and taken such actions as may be required by Agent in connection therewith; 
 (ix) concurrently with delivery of
the notice referred to in clause (i) above, Borrowers shall have delivered to Agent, in form and substance reasonably satisfactory to Agent: 
 (1) a pro forma consolidated balance sheet, income statement and cash flow statement of Holdings and its Subsidiaries (the “Acquisition Pro Forma”), based on the financial statements of
Holdings and its Subsidiaries most recently delivered to Agent pursuant to Annex E prior to the consummation of such Permitted Acquisition (and the financial statements of the Target as of the date of such financial statements of Holdings and
its Subsidiaries or, if financial statements of the Target are not available for such date, the financial statements of the Target dated as of a date no earlier than the date that is six months prior to the date on which the notice required by
Section 6.1(b)(i) is delivered to Agent), which shall be complete and shall fairly present in all material respects the assets, liabilities, financial condition and results of operations of Holdings and its Subsidiaries in accordance with GAAP
consistently applied, but taking into account such Permitted Acquisition and the funding of all Loans in connection therewith, and such Acquisition Pro Forma shall reflect that, on a pro forma basis, (A) no Event of Default has occurred and is
continuing or would result after giving effect to such Permitted Acquisition and (B) Borrowers would have been in compliance with the financial covenants set forth in Annex G for the four quarter period reflected in the Compliance
Certificate most recently delivered to Agent pursuant to Annex E prior to the consummation of such Permitted Acquisition (after giving effect to such Permitted Acquisition and all Loans funded in connection therewith as if made on the first
day of such period); 

  
 4 

 (2) updated versions of the most recently delivered Projections covering the
3-year period commencing on the date of such Permitted Acquisition and otherwise prepared in accordance with the Projections (the “Acquisition Projections”) and based upon historical financial data of a recent date reasonably
satisfactory to Agent, taking into account such Permitted Acquisition; 
 (3) a certificate of the chief
financial officer of Holdings and each Borrower to the effect that: (w) each Borrower (after taking into consideration all rights of contribution and indemnity such Borrower has against Holdings and each other Subsidiary of Holdings) will be
Solvent upon the consummation of the Permitted Acquisition; (x) the Acquisition Pro Forma fairly presents the financial condition of Holdings and its Subsidiaries (on a consolidated basis) as of the date thereof after giving effect to the
Permitted Acquisition; (y) the Acquisition Projections are reasonable estimates of the future financial performance of Holdings and its Subsidiaries subsequent to the date thereof based upon the historical performance of Holdings and its
Subsidiaries and the Target and show that Holdings and its Subsidiaries shall continue to be in compliance with the financial covenants set forth in Annex G for the 3-year period thereafter; and (z) Holdings and Borrowers have completed their
due diligence investigation with respect to the Target and such Permitted Acquisition, which investigation was conducted in a manner similar to that which would have been conducted by a prudent purchaser of a comparable business and the results of
which investigation were delivered to Agent and Lenders; and 
 (4) if the financial statements of the Target on
which the Acquisition Pro Forma is based are dated as of a date that is earlier than the date of the financial statements of Holdings and its Subsidiaries most recently delivered to Agent pursuant to Annex E prior to the consummation of such
Permitted Acquisition (as permitted by subclause (1) above), any subsequently-dated financial statements of the Target received by Holdings or any of its Subsidiaries prior to the date that is five Business Days prior to the scheduled closing
of such Permitted Acquisition; 

  
 5 

 (x) on or prior to the date of such Permitted Acquisition, Agent shall have
received, in form and substance reasonably satisfactory to Agent, copies of the acquisition agreement and related agreements and instruments, and all opinions, certificates, lien search results and other documents reasonably requested by Agent
including those specified in the last sentence of Section 5.9; 
 (xi) at the time of such Permitted
Acquisition and after giving effect thereto, no Default or Event of Default has occurred and is continuing; and 

(xii) after giving effect to any Permitted Acquisition with respect to which a Credit Party is funding any portion of such
investment, the aggregate amount of investments in Subsidiaries that are not Credit Parties shall not exceed the amount set forth in Section 6.2(g)(ii) (after giving effect to all other investments made under such
Section 6.2(g)(ii)). 
 Notwithstanding anything to the contrary contained herein, if operating
income of the Target for the most recently ended twelve fiscal months is greater than or equal to $5,000,000 and the purchase price of the Permitted Acquisition, including, without limitation, any assumed Indebtedness, is less than or equal to
$20,000,000, Borrowers shall not be required to deliver the items required in Section 6.1(b)(ix); provided that Borrowers shall be required to deliver (a) a balance sheet, income statement and cash flow statement of the Target for
the Fiscal Year most recently ended and interim financial statements, to the extent available, for the period from the most recently ended Fiscal Year to the date of such Permitted Acquisition, provided that, if such financial statements of
the Target are not available for the Fiscal Year most recently ended, then Borrower shall deliver such financial statements for the Target dated as of a date no earlier than the date that is six months prior to the date on which the notice required
by Section 6.1(b)(i) is delivered to Agent (and Borrower shall be required to deliver to Agent any subsequently-dated financial statements of the Target received by Holdings or any of its Subsidiaries prior to the date that is five Business
Days prior to the scheduled closing of such Permitted Acquisition), (b) projections of the Target covering the 1 year period commencing on the date of such Permitted Acquisition and (c) a certificate of the chief financial officer of
Holdings and each Borrower to the effect that (i) each Borrower (after taking into consideration all rights of contribution and indemnity such Borrower has against Holdings and each other Subsidiary of Holdings) will be Solvent upon the
consummation of the Permitted Acquisition, (ii) Holdings and Borrowers have completed their due diligence investigation with respect to the Target and such Permitted Acquisition, which investigation was conducted in a manner similar to that
which would have been conducted by a prudent purchaser of a comparable business and the results of which investigation were delivered to Agent and Lenders and (iii) after giving effect to such Permitted Acquisition, no Default or Event of
Default shall have occurred and be continuing.” 

  
 6 

 (f) Section 6.2(c) of the Credit Agreement is hereby amended and modified by deleting
such section in its entirety and inserting the following in lieu thereof: 
 “(c) each Credit Party, the
Foreign Stock Holding Company and each direct Foreign Subsidiary of any Credit Party or the Foreign Stock Holding Company may make any investment that constitutes or is otherwise permitted in connection with a Permitted Acquisition;”

 (g) Section 6.2(g) of the Credit Agreement is hereby amended and modified by deleting such section in its entirety and
inserting the following in lieu thereof: 
 “(g)(i) investments (A) by any Credit Party in another
Credit Party, (B) by any Foreign Subsidiary in another Foreign Subsidiary and (C) in the form of Indebtedness otherwise permitted by Section 6.3(a)(ix) and (ii) investments by Credit Parties in Subsidiaries that are not
Credit Parties so long as the aggregate amount of all such investments (excluding any such investments that are assumed and exist on the date any Permitted Acquisition is consummated and that are not made, incurred or created in contemplation of or
in connection with such Permitted Acquisition) made pursuant to this clause (ii) shall not exceed $55,000,000 (plus an amount equal to any returns of capital or sale proceeds actually received in cash by the Credit Parties in respect of any
such investments, which amount shall not exceed the amount of such investment valued at cost at the time such investment is made);” 
 (h) Section 6.2(i) of the Credit Agreement is hereby amended and modified by deleting such section in its entirety and inserting the following in lieu thereof: 

“(i) the Credit Parties and the other Subsidiaries may consummate the Foreign Subsidiary Reorganization; and”

 (i) Section 6.3(a)(x) of the Credit Agreement is hereby amended and modified by deleting such section in its entirety
and inserting the following in lieu thereof: 
 “(x) Indebtedness (A) of Foreign Subsidiaries owed to Credit Parties in
an aggregate outstanding amount not to exceed $80,000,000 less the amount of investments made by the Credit Parties pursuant to Section 6.2(h) and Section 6.2(g)(ii) and (B) of Foreign Operating Subsidiaries owed to any
other Foreign Subsidiary,” 

  
 7 

 (j) Section 6.3(a)(xii) of the Credit Agreement is hereby amended and modified by
deleting such section in its entirety and inserting the following in lieu thereof: 
 “(xii) other Indebtedness (including,
without limitation, repurchase obligations arising in connection with financing provided by certain financial institutions to certain dealers with respect to Inventory purchased by such dealers from Credit Parties) in an aggregate amount not to
exceed $20,000,000 at any time outstanding; provided, however, that any such other Indebtedness of Foreign Subsidiaries shall not exceed $10,000,000 in the aggregate at any time outstanding; provided, further, any such
Indebtedness owing by any Credit Party shall be unsecured, and” 
 (k) Section 6.4(a) of the Credit Agreement is
hereby amended and modified by adding the following sentence at the end of such section: 
 “The limitations set forth in
this Section 6.4(a) shall not prohibit (x) the consummation of the Foreign Subsidiary Reorganization or (y) sales, transfers, conveyances, assignments and other dispositions permitted by clauses (k) and (l) of
Section 6.8 so long as such transactions do not involve a Credit Party (other than transactions solely between or among Credit Parties).” 
 (l) Section 6.5 of the Credit Agreement is hereby amended and modified by deleting clause (b) of such section in its entirety and inserting the following in lieu thereof: 

“(b) except for (i) the Foreign Subsidiary Reorganization and (ii) mergers or amalgamations among Credit Parties or such
Subsidiaries, as applicable, specifically permitted under Section 6.1, make any change in its capital structure as described in Disclosure Schedule (3.8), including the issuance or sale of any shares of Stock (except Excluded
Stock Issuances), warrants or other securities convertible into Stock or any revision of the terms of its outstanding Stock; provided that Holdings may issue or sell shares of its Stock for cash so long as (i) the cash proceeds thereof,
if any, are applied in prepayment of the Obligations to the extent required by Section 1.3(b)(iii), and (ii) no Change of Control occurs after giving effect thereto” 

(m) Section 6.6 of the Credit Agreement is hereby amended and modified by deleting such section in its entirety and inserting the
following in lieu thereof: 
 “6.6 Guaranteed Indebtedness. No Credit Party shall, or shall permit any Subsidiary of
any Credit Party to, create, incur, assume or permit to exist any Guaranteed Indebtedness except (a) by endorsement of instruments or items of payment for deposit to the general account of any Credit Party or such Subsidiary, (b) for
Guaranteed Indebtedness incurred for the benefit of any other Credit Party if the primary obligation is expressly permitted by this Agreement, (c) for Guaranteed Indebtedness permitted under Section 6.3(a)(v) or
Section 6.3(a)(xii) with respect to repurchase obligations arising in connection with financing provided by certain financial institutions to certain dealers with respect to Inventory purchased by such dealers from Credit Parties, and
(d) for Guaranteed Indebtedness incurred by a Foreign Operating Subsidiary for the benefit of any other Foreign Operating Subsidiary if the primary obligation is expressly permitted by this Agreement.” 

  
 8 

 (n) Section 6.7(d) of the Credit Agreement is hereby amended and modified by deleting
such section in its entirety and inserting the following in lieu thereof: 
 “(d) Liens securing Indebtedness permitted
under (A) Section 6.3(a)(xi) to the extent such Liens are solely on property of the issuer of such Indebtedness, (B) Section 6.3(a)(xiii)(B) to the extent such Liens are solely on the assets or Stock of the Target
or its Subsidiaries or (C) solely with respect to Indebtedness owing by a Foreign Operating Subsidiary, Indebtedness of such Foreign Operating Subsidiary permitted under Section 6.3(a)(xii).” 

(o) Section 6.8 of the Credit Agreement is hereby amended and modified by deleting the last sentence of such section in its entirety
and adding the following text immediately following clause (h) of such section: 
 “, (i) the transfer of the
Stock of the Foreign Operating Subsidiaries to the Foreign Stock Holding Company in connection with the Foreign Subsidiary Reorganization, (j) subject to the limitations set forth in Section 6.4(a), Section 6.20 and, in
the case of any transaction in the form of an investment, Sections 6.2(g) and (h), any sale, transfer, conveyance, assignment or other disposition of any property or other assets from any Credit Party to any Foreign Subsidiary so long
as (1) the applicable Credit Party shall have provided prior written notice of any such transaction that is not in the form of a cash investment (together with supporting documentation establishing the fair market value of any such property or
asset so transferred in form and substance reasonably satisfactory to Agent) and (2) the aggregate fair market value of all sales, transfers, conveyances, assignments or other dispositions of any property or other assets that is not in the form
of an investment permitted by Sections 6.2(g) or (h) shall not exceed $25,000,000 (or such greater amount as may be approved in writing by Agent) during the term of this Agreement, (k) subject to the limitations contained in
Section 5.15 and Section 6.20, any transfer, conveyance, sale, assignment or other disposition of any property or other assets from any Foreign Subsidiary to any other Foreign Subsidiary and (l) any transfer, conveyance,
sale, assignment or other disposition of any property or other assets from any Credit Party or any of their respective Subsidiaries to any Credit Party. With respect to any disposition of assets or other properties permitted pursuant to clauses
(b), (c), (d), (f), (g), (h), (i) or (j) above, subject to Section 1.3(b), Agent agrees on reasonable prior written notice to release its Lien on such assets or other
properties in order to permit the applicable Credit Party to effect such disposition and shall execute and deliver to Borrowers, at Borrowers’ expense, appropriate UCC-3 termination statements and other releases as are reasonably requested by
Borrowers.” 

  
 9 

 (p) Section 6 of the Credit Agreement is hereby amended by adding the following
Section 6.20 immediately following Section 6.19: 
 “6.20 Business of Foreign Subsidiaries. No Credit Party
shall, or shall permit any of its Subsidiaries to, permit (a) (i) BIH CV to engage at any time in any business or business activity other than (A) ownership and acquisition of Stock in the Foreign Stock Holding Company,
(B) performance of its obligations under and in connection with the Loan Documents, (C) actions required to maintain its existence, (D) the ownership of any Intellectual Property conveyed or otherwise transferred to BIH CV in
accordance with Section 6.8 and Section 6.2(g) and (E) activities incidental to its maintenance and continuance and to the foregoing activities; (ii) BIH CV to incur any Indebtedness (other than Indebtedness owing
by BIH CV to (A) any Credit Party, (B) the Foreign Stock Holding Company or (C) so long as such Indebtedness is not subject to any Lien in favor of any other Person, any Foreign Operating Subsidiary); (iii) BIH CV to make
investments other than (A) ownership interests in the Stock of the Foreign Stock Holding Company, (B) capital contributions to the Foreign Stock Holding Company and (C) intercompany loans or advances made to any Credit Party or any
Foreign Subsidiary so long as any such loan to a Credit Party is subordinated to the Obligations on terms and conditions reasonably acceptable to Agent; or (iv) BIH CV to sell, dispose of, grant a Lien on or otherwise transfer the Stock of the
Foreign Stock Holding Company or (b)(i) the Foreign Stock Holding Company to engage at any time in any business or business activity other than (A) ownership and acquisition of Stock in Foreign Operating Subsidiaries, (B) performance of
its obligations under and in connection with the Loan Documents, (C) actions required to maintain its existence, (D) the ownership of any Intellectual Property conveyed or otherwise transferred to the Foreign Stock Holding Company in
accordance with Section 6.8 and Section 6.2(g) and (E) activities incidental to its maintenance and continuance and to the foregoing activities; (ii) the Foreign Stock Holding Company to incur any Indebtedness
(other than Indebtedness owing by the Foreign Stock Holding Company to (A) any Credit Party, (B) BIH CV or (C) any Foreign Operating Subsidiary so long as such Indebtedness is not subject to any Lien in favor of any other Person);
(iii) the Foreign Stock Holding Company to make investments other than (A) ownership interests in the Stock of its Foreign Operating Subsidiaries, (B) capital contributions to any Foreign Operating Subsidiary and (C) intercompany
loans or advances made to any Credit Party or any Foreign Subsidiary so long as any such loan to a Credit Party is subordinated to the Obligations on terms and conditions reasonably acceptable to Agent; or (iv) the Foreign Stock Holding Company
to sell, dispose of, grant a Lien on or otherwise transfer the Stock of any Foreign Operating Subsidiary except as otherwise permitted under Section 6.8 and Section 5.15.” 

  
 10 

 (q) Section 6 of the Credit Agreement is hereby amended by adding the following
Section 6.21 immediately following Section 6.20: 
 “6.21 Foreign Subsidiary Reorganization.
Notwithstanding any provision hereof to the contrary, the Credit Parties shall not be permitted to consummate any transaction contemplated by clause (b) of the definition of “Foreign Subsidiary Reorganization” until each of the
following conditions shall have been satisfied: (a) Agent shall have received certified copies of the documents evidencing the formation and organization of BIH CV and the Foreign Stock Holding Company and the restructuring and transfer of the
Stock of the Foreign Operating Subsidiaries as described herein, in each case in form and substance reasonably satisfactory to Agent, and (b) Agent shall have received a pledge agreement granting Agent a first-priority perfected Lien in 65% of
the outstanding Stock of BIH CV, together with stock certificates, stock powers and any other instruments necessary to perfect such pledge and opinions of local counsel with respect to such pledge, in each case in form and substance reasonably
satisfactory to Agent.” 
 (r) Annex A to the Credit Agreement, Definitions, is hereby modified and amended
by inserting the following definitions in the appropriate alphabetical order therein: 
 “BIH CV” means a
company to be organized under the laws of the Netherlands that shall become a Subsidiary of one or more Credit Parties in connection with the Foreign Subsidiary Reorganization. It is understood and agreed that BIH CV shall be a holding company (with
the principal assets of such Subsidiary being the Stock of the Foreign Stock Holding Company and other assets incidental to its operations and such other assets as permitted by Section 6.20). 

“First Amendment” means that certain First Amendment to Third Amended and Restated Credit Agreement, dated as of the
First Amendment Effective Date, among the Borrowers, Agent and the Lenders. 
 “First Amendment Effective Date”
means January     , 2011. 
 “Foreign Operating Subsidiary” means any Foreign
Subsidiary other than the Foreign Stock Holding Company or BIH CV. 
 “Foreign Stock Holding Company” means a
company to be organized under the laws of the Netherlands that will become a Subsidiary of BIH CV in connection with the Foreign Subsidiary Reorganization. It is understood and agreed that the Foreign Stock Holding Company shall be a holding company
(with the principal assets of such Subsidiary being the Stock of Foreign Subsidiaries and other assets incidental to its operations and such other assets as permitted by Section 6.20). 

“Foreign Subsidiary Reorganization” means that series of intercompany transactions occurring on or after the First
Amendment Effective Date pursuant to which (a) first, BIH CV and the Foreign Stock Holding Company are organized and become Subsidiaries, subject to Section 5.15 and (b) second, except as otherwise indicated on
Disclosure Schedule (5.15), the Stock of each Foreign Operating Subsidiary owned by a Credit Party as of the First Amendment Effective Date is sold or otherwise transferred to, and each such Foreign Operating Subsidiary becomes a direct subsidiary
of, the Foreign Stock Holding Company. Immediately after giving effect to the Foreign Subsidiary Reorganization, the issued and outstanding Stock of each Subsidiary of Holdings will be owned by the Persons and in the amounts set forth on Disclosure
Schedule (5.15). 

  
 11 

 (s) Annex A to the Credit Agreement, Definitions, is hereby modified and
amended by deleting the definition of “Interest Payment Date” and replacing it with the following: 

“Interest Payment Date” means (a) as to any Index Rate Loan, the first day of each month to occur while such Loan
is outstanding, and (b) as to any LIBOR Loan, the last day of the applicable LIBOR Period; provided that, in addition to the foregoing, each of (x) the date upon which all of the Commitments have been terminated and the Loans have
been paid in full and (y) the Commitment Termination Date shall be deemed to be an “Interest Payment Date” with respect to any interest that has then accrued under this Agreement. 

(t) The Credit Agreement is further modified and amended by inserting the attached Disclosure Schedule (5.15), Foreign Subsidiary
Reorganization, in the appropriate numerical order within the Credit Agreement. 
 2. No Other Consents or Amendments.
Except as otherwise expressed herein, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of Agent and Lenders under the Credit Agreement or any of the other Loan Documents, nor
constitute a waiver of any provision of the Credit Agreement or any of the other Loan Documents. Except for the amendments and consent set forth above, the text of the Credit Agreement and all other Loan Documents shall remain unchanged and in full
force and effect and each Credit Party hereby ratifies and confirms its obligations thereunder. This Amendment shall not constitute a modification of the Credit Agreement or any other Loan Document or a course of dealing between Borrowers and the
other Credit Parties, on the one hand, and Lenders, on the other hand, at variance with the Credit Agreement or any other Loan Document such as to require further notice by Lenders to Borrowers or such Credit Parties to require strict compliance
with the terms of the Credit Agreement and the other Loan Documents in the future, except as expressly set forth herein. Each Borrower and each other Credit Party acknowledges and expressly agrees that Lenders reserve the right to, and do in fact,
require strict compliance with all terms and provisions of the Credit Agreement and the other Loan Documents. Neither any Borrower nor any other Credit Party has knowledge of any challenge to Lenders’ claims arising under the Loan Documents or
the effectiveness of the Loan Documents. 
 3. Conditions Precedent to Effectiveness. This Amendment shall be effective
as of the date first written above upon satisfaction of the following: 
 (a) Agent’s receipt of a counterpart hereof duly
executed by Borrowers, Credit Parties and each Lender; and 
 (b) the representations and warranties of Borrowers and other
Credit Parties contained in this Amendment shall be true and accurate in all respects (or, with respect to any representation or warranty that is not otherwise qualified as to materiality, in all material respects). 

  
 12 

 4. Representations and Warranties of Borrowers and Other Credit Parties. The Credit
Parties executing this Amendment, jointly and severally, make the following representations and warranties to Agent and each Lender with respect to all Credit Parties, each and all of which shall survive the execution and delivery of this Amendment:

 (a) this Amendment has been executed and delivered by duly authorized representatives of each Credit Party, and the Credit
Agreement, as modified and amended by this Amendment, constitutes a legal, valid and binding obligation of each Credit Party, and is enforceable against each Credit Party in accordance with its terms; 

(b) no Default or Event of Default has occurred or is continuing; and 

(c) all of the representations and warranties of each Credit Party contained in the Credit Agreement continue to be true and correct in
all material respects as of the date hereof as though made on and as of such date, except to the extent that such representation or warranty expressly relates to an earlier date or except for changes therein expressly permitted or expressly
contemplated by the Credit Agreement, as amended hereby. 
 5. Effect on the Credit Agreement and other Loan Documents.
Except as specifically provided herein, the Credit Agreement and the other Loan Documents shall remain in full force and effect, and are hereby ratified, reaffirmed and confirmed. This Amendment shall be deemed to be a Loan Document for all
purposes. 
 6. Costs and Expenses. Each Borrower, jointly and severally, agrees to pay on demand all fees, costs and
expenses incurred in connection with the preparation, execution, delivery, administration, modification and amendment of this Amendment and the other instruments and documents to be delivered hereunder, including, without limitation, the reasonable
fees, costs and expenses of counsel for Agent with respect thereto and with respect to advising Agent as to its rights and responsibilities hereunder and thereunder. 
 7. Counterparts. This Amendment may be executed in any number of separate counterparts and by the different parties hereto on separate counterparts, each of which shall be deemed an original and
all of which, taken together, shall be deemed to constitute one and the same instrument. In proving this Amendment in any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party
against whom such enforcement is sought. Any signatures delivered by a party by facsimile or other electronic transmission shall be deemed an original signature hereto. 

  
 13 

 8. GOVERNING LAW. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AMENDMENT, IN ALL
RESPECTS, INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, THIS AMENDMENT AND THE OBLIGATIONS SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS
MADE AND PERFORMED IN THAT STATE AND ANY APPLICABLE LAWS OF THE UNITED STATES OF AMERICA. EACH CREDIT PARTY HEREBY CONSENTS AND AGREES THAT THE STATE OR FEDERAL COURTS LOCATED IN NEW YORK COUNTY, CITY OF NEW YORK, NEW YORK SHALL HAVE EXCLUSIVE
JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN THE CREDIT PARTIES, AGENT AND LENDERS PERTAINING TO THIS AMENDMENT OR ANY OF THE OTHER LOAN DOCUMENTS OR TO ANY MATTER ARISING OUT OF OR RELATING TO THIS AMENDMENT OR ANY OF THE OTHER
LOAN DOCUMENTS; PROVIDED, THAT AGENT, LENDERS AND THE CREDIT PARTIES ACKNOWLEDGE THAT ANY APPEALS FROM THOSE COURTS MAY HAVE TO BE HEARD BY A COURT LOCATED OUTSIDE OF NEW YORK COUNTY; PROVIDED FURTHER, THAT NOTHING IN THIS
AMENDMENT SHALL BE DEEMED OR OPERATE TO PRECLUDE AGENT FROM BRINGING SUIT OR TAKING OTHER LEGAL ACTION IN ANY OTHER JURISDICTION TO REALIZE ON THE COLLATERAL OR ANY OTHER SECURITY FOR THE OBLIGATIONS, OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN
FAVOR OF AGENT, AND CREDIT PARTIES MAY MAKE ANY COUNTERCLAIMS RELATING TO THE SAME MATTER, REQUESTS FOR EQUITABLE RELIEF RELATING TO THE SAME MATTER OR AFFIRMATIVE DEFENSES IN CONNECTION THEREWITH. EACH CREDIT PARTY EXPRESSLY SUBMITS AND CONSENTS IN
ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND EACH CREDIT PARTY HEREBY WAIVES ANY OBJECTION THAT SUCH CREDIT PARTY MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON
CONVENIENS AND HEREBY CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT. EACH CREDIT PARTY HEREBY WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR
SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINTS AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO SUCH CREDIT PARTY AT THE ADDRESS SET FORTH IN ANNEX I OF THE CREDIT AGREEMENT AND THAT SERVICE SO MADE SHALL
BE DEEMED COMPLETED UPON THE EARLIER OF SUCH CREDIT PARTY’S ACTUAL RECEIPT THEREOF OR 3 DAYS AFTER DEPOSIT IN THE UNITED STATES MAILS, PROPER POSTAGE PREPAID. 
 [The remainder of the page is intentionally blank.] 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment or caused it to be
executed under seal by their duly authorized officers, as of the day and year first written above. 
  

			
	BORROWERS:
	
	BLOUNT, INC., a Delaware corporation
		
	By:	 	         /s/ Calvin E. Jenness

Name: Calvin E. Jenness

		 	Title: Senior Vice President
	
	 OMARK PROPERTIES, INC., an Oregon
 corporation

		
	By:	 	         /s/ Richard H. Irving, III

		 	 Name: Richard H. Irving, III

Title: Vice President

	
	 WINDSOR FORESTRY TOOLS LLC, a
 Tennessee limited liability company

	
	By: Blount, Inc., its sole member
		
	By:	 	         /s/ Calvin E. Jenness

		 	 Name: Calvin E. Jenness

Title: Senior Vice President

 FIRST AMENDMENT TO CREDIT AGREEMENT 

 
			
	AGENT AND LENDERS:
	
	GENERAL ELECTRIC CAPITAL
	CORPORATION, as Agent and a Lender
		
	By:	 	         /s/ Judith Langan

	Name:	 	Judith Langan
	Title:	 	Duly Authorized Signatory

 FIRST
AMENDMENT TO CREDIT AGREEMENT 

 
			
	The following Persons are signatories to this Agreement in their capacity as Credit Parties and not as Borrowers.
	
	CREDIT PARTIES:
	
	 BLOUNT INTERNATIONAL, INC., a Delaware
 corporation

		
	By:	 	         /s/ Richard H. Irving, III

		 	 Name: Richard H. Irving, III

Title: Senior Vice President

	
	BI, L.L.C., a Delaware limited liability company
	
	By: Blount, Inc., its managing member
		
	By:	 	         /s/ Calvin E. Jenness

		 	 Name: Calvin E. Jenness

Title: Senior Vice President

	
	4520 CORP., INC., a Delaware corporation
		
	By:	 	         /s/ Richard H. Irving, III

		 	 Name: Richard H. Irving, III

Title: Vice President

	
	SP COMPANIES, INC., a Delaware corporation
		
	By:	 	         /s/ Calvin E. Jenness

		 	 Name: Calvin E. Jenness

Title: Vice President

	
	 SPEECO, INCORPORATED, a Delaware
 corporation

		
	By:	 	         /s/ Richard H. Irving, III

		 	 Name: Richard H. Irving, III

Title: Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]